GDC-0927

• UNSPSC Description:

  GDC-0927 (SRN-927) is a potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist[1].

• Target Antigen:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/GDC-0927.html

• Purity:

  99.98

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=C2C(C(C)=C(C3=CC=CC(O)=C3)[C@H](C4=CC=C(OCCN5CC(CF)C5)C=C4)O2)=C1

• Molecular Weight:

  461.52

• References & Citations:

  [1]MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  1642297-01-5